Myocardium-restricted transgenic overexpression of methionine sulfoxide reductase A, an enzyme reducing CaMKII oxidation, effectively ameliorated susceptibility for AF in angiotensin-2 treated mice, suggesting CaMKII oxidation as a viable therapeutic target in AF [64]. The gene discussed is CAMK2G; the disease is atrial fibrillation.